In IBD, and in medicine in general, it is increasingly important to identify those actions that do not add value (and can harm) and concentrate our efforts on what benefits our patients. Let's avoid “too much medicine”
cghjournal.org/article/S1542-…

Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis. #IBD .
GUTJournal_BMJ

pubmed.ncbi.nlm.nih.gov/38684238/

Y-ECCO Florian Rieder Fernando Gomollón

….. balancing benefit/risk on the single patient, then 3 hierarchical points.
Not necessary avoiding colectomy at any cost, indeed…. x.com/jonathansegal8…

… but always balancing benefit/risk on the single patient.
Dogmas in ASUC (descending order):
1) avoid mortality
2) avoid colectomy
3) reduce drug-related AEs and hospital stay

Delighted to see 🇬🇧 PANTS study 3 year extension data published in The Lancet Gastroenterology & Hepatology
🙏🏼 to the investigators and patients who participated
sciencedirect.com/science/articl…

⏺️Only 1/3 of those treated with TNFis remain in remission at 3years
⏺️Week 14 levels significant in reducing…

Crohn's disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate: A retrospective multicentre real-world study onlinelibrary.wiley.com/doi/10.1111/ap… via alessandro armuzzi et al Seb

I think that all of them are important. And probably we have to understand better our at risk-of-recurrence criteria ….

Hot off the press, online on AP&T. Crohn’s disease after surgery: despite increased post-operative use of IMMs and anti-TNFα agents in the last two decades, the impact of these strategies on the risk of long-term re-operation rate has been modest onlinelibrary.wiley.com/doi/10.1111/ap…

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications. ⁦Gut Journal⁩ gut.bmj.com/content/early/…

SuperNacho!

LOTS of great opportunities to join ECCO committees & work with colleagues all around the world - our aim being to improve lives of patients living with IBD🌍

Check out link below & especially consider applying to young ECCO for all who are eligible👥

ecco-ibd.eu/about-ecco/ecc…

Deep dive on Standards of Care in IBD! #GEDII2024 concludes with an advanced course on the crucial topic of standardizing care for #IBD from both physician & patient perspectives!

Ensuring effective & consistent treatment while prioritizing patient needs.

See you next year!

Manuel Barreiro alessandro armuzzi Fernando Magro Paula Ministro francisco portela

Amazing dinner and better company in @gedii THANKS Fernando Magro Y-ECCO alessandro armuzzi

📢Day 2 of #GEDII2024 is here

No drug like the first: Optimizing initial treatment for IBD alessandro armuzzi
Tackling refractory IBD patients: New strategies for tough cases Vipul Jairath MBChB DPhil
Balancing the tightrope: Finding the sweet spot between efficacy & safety #LaurentBeaugerie

Thoughtful session on IBD therapies ⁦GEDII⁩ 2024 annual congress. The first (any) drug is always better, managing the refractory patient, balancing effectiveness and safety. ⁦Vipul Jairath MBChB DPhil⁩ ⁦Laurent Beaugerie⁩ ⁦alessandro armuzzi⁩ ⁦GEDII⁩

It’s all about strategy ⁦GEDII⁩ annual congress. ⁩ ⁦Uri Kopylov⁩ ⁦⁦Vipul Jairath MBChB DPhil⁩ ⁦alessandro armuzzi⁩ ⁦GEDII⁩

First round table in GEDII meeting
-AI In IBD endoscopy Uri Kopylov
-Personalized medicine Dr Noor
-Targets in UC: From histology to mucosal healing Fernando Magro
!

Proud to have been invited to such an important meeting as GEDII GEDII with a high number of delegates
Very happy to give two of my favorite lectures 'pouchitis' and 'IBD Units Program in Spain'

Fernando Magro Manuel Barreiro alessandro armuzzi Uri Kopylov Vipul Jairath MBChB DPhil @nuru_noor1

#IBD twitter #IBD